Skip to main content

Table 1 Demographic and clinicopathological information (n = 83)

From: Changes in peripheral lymphocyte populations in patients with advanced/recurrent ovarian cancer undergoing splenectomy during cytoreductive surgery

Variables Splenectomy (n = 20) Non-splenectomy (n = 63) P-value
Age (years), mean (SD, 95% CI) 58 (9.7, 53–62) 54 (8.8, 52–56) 0.114*
Neoadjuvant chemotherapy (%) 2 (10%) 0 0.056#
Histology
 High-grade serous carcinoma 18 (90.0%) 55 (87.3%) 0.246#
 Clear cell carcinoma 0 5 (7.9%)
 Endometrioid 1 (5.0%) 1 (1.6%)
 Carcinosarcoma 1 (5.0%) 0
 Low-grade serous carcinoma 0 2 (3.2%)
 Pre-treatment CA125 (U/mL), media (range) 718.9 (8.9–5000) a 539.0 (8.3–5000) 0.446**
FIGO stage (%)
 IIIC 11 (55.0%) 33 (52.4%) 0.838#
 IV 3 (15.0%) 14 (22.2%)
 Recurrence 6 (30.0%) 16 (25.4%)
Residual disease (%)
 0 13 (65.0%) 40 (63.5%) 0.903#
  ≤ 1 cm (optimal) 7 (35.0%) 23 (36.5%)
Platinum response (%) b
 Sensitive 14 (70.0%) 51 (81.0%) 0.185#
 Resistant 6 (30.0%) 9 (14.3%)
  1. P-value < 0.05 was deemed statistically significant
  2. Abbreviations: FIGO   The International Federation of Gynecology and Obstetrics, CA125 Cancer Antigen 125
  3. a The upper limit of CA 125 detection is 5000
  4. b Sixteen patients in the splenectomy group and 40 patients in the control group were available for platinum response assessment
  5. * Independent-Sample T-test
  6. ** Mann–Whitney U test
  7. # chi-square or Fisher’s exact test